- Home
- RFAI vs DMAC Comparison
RFAI vs DMAC Comparison
Compare RFAI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFAI
- DMAC
- Stock Information
- Founded
- RFAI 2024
- DMAC 2000
- Country
- RFAI Singapore
- DMAC United States
- Employees
- RFAI N/A
- DMAC N/A
- Industry
- RFAI
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- RFAI
- DMAC Health Care
- Exchange
- RFAI NYSE
- DMAC Nasdaq
- Market Cap
- RFAI 157.3M
- DMAC 158.1M
- IPO Year
- RFAI 2024
- DMAC N/A
- Fundamental
- Price
- RFAI $10.49
- DMAC $4.11
- Analyst Decision
- RFAI
- DMAC Strong Buy
- Analyst Count
- RFAI 0
- DMAC 2
- Target Price
- RFAI N/A
- DMAC $8.00
- AVG Volume (30 Days)
- RFAI 14.1K
- DMAC 102.4K
- Earning Date
- RFAI 01-01-0001
- DMAC 05-13-2025
- Dividend Yield
- RFAI N/A
- DMAC N/A
- EPS Growth
- RFAI N/A
- DMAC N/A
- EPS
- RFAI 0.32
- DMAC N/A
- Revenue
- RFAI N/A
- DMAC N/A
- Revenue This Year
- RFAI N/A
- DMAC N/A
- Revenue Next Year
- RFAI N/A
- DMAC N/A
- P/E Ratio
- RFAI $32.83
- DMAC N/A
- Revenue Growth
- RFAI N/A
- DMAC N/A
- 52 Week Low
- RFAI $10.00
- DMAC $2.14
- 52 Week High
- RFAI $10.50
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- RFAI N/A
- DMAC 50.90
- Support Level
- RFAI N/A
- DMAC $3.92
- Resistance Level
- RFAI N/A
- DMAC $4.33
- Average True Range (ATR)
- RFAI 0.00
- DMAC 0.29
- MACD
- RFAI 0.00
- DMAC 0.02
- Stochastic Oscillator
- RFAI 0.00
- DMAC 56.79
About RFAI RF ACQUISITION CORP II
RF Acquisition Corp II is a blank check company.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.